Skip to content

Author

Q. Van Thillo

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cardiovascular risk and disease in haemophilia a patients: the comor-HA cohort study

– Haemophilia A is a congenital bleeding disorder, which can be treated with factor VIII (FVIII) products and emicizumab, a bispecific monoclonal antibody mimicking endogenous factor VIII. These advances in prophylactic and on-demand haemostatic therapies have dramatically increased life expectancy in haemophilia...

M. Erard, L. Bommarez, M. Jeurissen et al. · 0 citations
Open access Oct 2026

Clinical efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII in long-term prophylaxis study in patients older than 6 years with severe von Willebrand disease

Prophylactic treatment using a plasma-derived von Willebrand factor (pdVWF, Wilfactin®) was safe and effective in clinically severe VWD.

Cédric Hermans, B. Meddeb, Q. Van Thillo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.